Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Churg-Strauss syndrome is a rare type of systemic vasculitis which occurs almost exclusively
in patients with asthma and which is characterized by prominent blood and tissue
eosinophilia. The disease has a chronic smoldering course with a permanent need for medium to
high corticosteroid doses. Available unselective immunosuppressive agents are often
insufficient to reduce corticosteroid doses, to induce complete remission and to protect
patients from disease flares which occur in more than 50 % of cases.
Interleukin-5 is the most potent cytokine regulating the production of eosinophil
granulocytes which are the major effector cells in Churg-Strauss syndrome. Recently, an
increased production of interleukin-5 was demonstrated in Churg-Strauss syndrome. Mepolizumab
is a monoclonal IgG antibody targeting interleukin-5 and is effective in the treatment of the
HES. The hypothesis of this study is, that mepolizumab will induce remission and allow for
steroid reduction.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Schleswig-Holstein University of Schleswig-Holstein